Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
Willems, Evelyne ; Humblet-Baron, Stéphanie ; Dengis, Olivier et al
in Bone Marrow Transplantation (2010), 45Detailed reference viewed: 11 (3 ULg)
Regulatory T cells in Wiskott-Aldrich syndrome and after allogeneic transplantation with nonmyeloablative conditioning
Doctoral thesis (2009)Detailed reference viewed: 18 (3 ULg)
Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Humblet-Baron, Stéphanie ; Baron, Frédéric ; et al
in Transplantation (2003), 76(10), 1531-2Detailed reference viewed: 26 (5 ULg)
T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
Baron, Frédéric ; Schaaf-Lafontaine, Nicole ; Humblet-Baron, Stéphanie et al
in Transplantation (2003), 76(12), 1705-13
BACKGROUND: We have previously shown that CD8 depletion or CD34 selection of peripheral blood stem cells (PBSC) reduced the incidence of acute graft-versus-host disease (GvHD) after nonmyeloablative stem ... [more ▼]
BACKGROUND: We have previously shown that CD8 depletion or CD34 selection of peripheral blood stem cells (PBSC) reduced the incidence of acute graft-versus-host disease (GvHD) after nonmyeloablative stem-cell transplantation (NMSCT). In this study, we analyze the effect of CD8 depletion or CD34 selection of the graft on early T-cell reconstitution. METHODS: Nonmyeloablative conditioning regimen consisted in 2 Gy total-body irradiation (TBI) alone, 2 Gy TBI and fludarabine, or cyclophosphamide and fludarabine. Patients 1 to 18 received unmanipulated PBSC, patients 19 to 29 CD8-depleted PBSC, and patients 30 to 35 CD34-selected PBSC. RESULTS: T-cell counts, and particularly CD4+ and CD4CD45RA+ counts, remained low the first 6 months after nonmyeloablative stem-cell transplantation (NMSCT) in all patients. CD34 selection (P<0.0001) but not CD8 depletion of PBSC significantly decreased T-cell chimerism. Donor T-cell count was similar in unmanipulated compared with CD8-depleted PBSC recipients but was significantly lower in CD34-selected PBSC recipients (P=0.0012). T cells of recipient origin remained stable over time in unmanipulated and CD8-depleted PBSC patients but expanded in some CD34-selected PBSC recipients between day 28 and 100 after transplant. Moreover, whereas CD8 depletion only decreased CD8+ counts (P<0.047), CD34 selection reduced CD3+(P<0.001), CD8+(P<0.016), CD4+ (P<0.001), and CD4+CD45RA+ (P<0.001) cell counts. T-cell repertoire was restricted in all patients on day 100 after hematopoietic stem-cell transplantation but was even more limited after CD34 selection (P=0.002). CONCLUSIONS: Despite of the persistence of a significant number of T cells of recipient origin, T-cell counts were low the first 6 months after NMSCT. Moreover, contrary with CD8 depletion of the graft that only affects CD8+ lymphocyte counts, CD34 selection dramatically decreased both CD8 and CD4 counts. [less ▲]Detailed reference viewed: 83 (8 ULg)
Comment je traite ... la leucemie myeloide chronique (LMC).
Hafraoui, Kaoutar ; Humblet-Baron, Stéphanie ; Baron, Frédéric et al
in Revue Médicale de Liège (2003), 58(1), 7-12
This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine ... [more ▼]
This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient. [less ▲]Detailed reference viewed: 213 (6 ULg)
Traitement moléculaire du cancer: le STI571, un inhibiteur des tyrosines kinases
Humblet-Baron, Stéphanie ; Baron, Frédéric ; Pirson, Laurence et al
in Revue Médicale Suisse (2002), 60(598), 1504-1508Detailed reference viewed: 118 (20 ULg)